Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MC4R | P32245 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4055295 | 0.89 | ALDH1A1 (0.43) | SMN1; SMN2CYP2D6HTR2BKMT2ACYP2C19 | |
| SCHEMBL30997647 | 0.83 | TSHR (0.49) | SMN1; SMN2KDM4ECYP2D6OPRM1KMT2A | |
| SCHEMBL30997646 | 0.83 | TSHR (0.49) | SMN1; SMN2KDM4ECYP2D6OPRM1KMT2A | |
| SCHEMBL30730934 | 0.82 | ACHE (0.42) | SMN1; SMN2KDM4E | |
| SCHEMBL1829575 | 0.79 | KDM1A (0.46) | SMN1; SMN2CYP2D6HTR2BKMT2ACYP2C19 | |
| SCHEMBL1752645 | 0.79 | KDM1A (0.50) | KDM4ECYP2D6HTR2BKCNH2KMT2A | |
| SCHEMBL2234081 | 0.79 | ADRA2C (0.52) | SMN1; SMN2KDM4ECYP2D6KMT2APOLB | |
| SCHEMBL5255784 | 0.79 | CTSD (0.39) | SMN1; SMN2HRH4 | |
| SCHEMBL1000959 | 0.79 | L3MBTL1 (0.50) | SMN1; SMN2CYP2D6KMT2APOLBCYP2C19 | |
| SCHEMBL1399603 | 0.78 | CHRNA7 (0.53) | SMN1; SMN2KDM4EADRA2AKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118924749-A | Preparation method of chromone amide compound for Alzheimer disease drug | 广西民族大学 | 2024-11-12 | — | — | CN | claimed |
| CN-115304550-A | Piperazine phenyl amino substituted pyrimidine amino acid derivative, preparation method and application | 南通大学 | 2022-11-08 | — | — | CN | claimed |
| CN-118924749-A | Preparation method of chromone amide compound for Alzheimer disease drug | 广西民族大学 | 2024-11-12 | — | — | CN | disclosed |
| EP-4419529-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-116829558-A | Compounds of formula (I) | 艾斯法姆生物技术股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-115160340-B | Small molecular compound with ACK1 inhibition activity and application thereof | 四川大学华西医院 | 2023-07-21 | — | — | CN | disclosed |
| CN-116456985-A | Pyrimidine and pyridine derivatives as HPK1 modulators and methods of use thereof | 深圳市原力生命科学有限公司 | 2023-07-18 | — | — | CN | disclosed |
| WO-2023069959-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| CN-115304550-A | Piperazine phenyl amino substituted pyrimidine amino acid derivative, preparation method and application | 南通大学 | 2022-11-08 | — | — | CN | disclosed |
| EP-3604306-B1 | MACROCYCLIC DERIVATIVE OF PYRAZOL[3,4-D]PYRIMIDIN-3-ONE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2022-10-26 | — | — | EP | disclosed |
| CN-115160340-A | Small molecule compound with ACK1 inhibitory activity and application thereof | 四川大学华西医院 | 2022-10-11 | — | — | CN | disclosed |
| CN-103121972-A | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG | 2013-05-29 | — | — | CN | disclosed |
| WO-2013059485-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF KINASES | ABBVIE INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-7956185-B2 | Cyclobut-3-ene-1,2,-dione inhibitors of polo-like kinases | ABBOTT LABORATORIES (US) | 2011-06-07 | — | — | US | disclosed |
| EP-2086540-B8 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2011-03-02 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| EP-2086540-A1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008065198-A1 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-06-05 | — | — | WO | disclosed |
| US-20080015192-A1 | INHIBITORS OF POLO-LIKE KINASES | ABBVIE INC. | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015192-A1 | INHIBITORS OF POLO-LIKE KINASES | PLK1, PLK2, BUB1B | SMN1; SMN2 2464/4885KDM4E 3120/4885MC4R 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.